Skip to main content
Signal8

BriaCell Therapeutics Corp. (BCTXL)

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

NASDAQ:BCTXLSub-class of BCTXHealthcare
-2.44%$0.8000
CLOSED
Mkt Cap$6.99M
EV-
Float8.72M
O/S8.73M
VOL79K sh
$ Vol$63K
RVOL4.64×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
BriaCell Therapeutics Corp. logoNASDAQ:BCTXLClosed$0.8000-2.44%